Christopher Seet received a $2.9 million R37 MERIT Award from NCI to advance the development of innovative T cell therapies for cancer. He is an assistant professor of hematology-oncology at the David Geffen School of Medicine at UCLA.
NCI is temporarily reducing its paylines as the federal government is being funded at FY2024 levels via a continuing resolution that extends until Dec. 20, delaying the budgeting process for most federal agencies in the new fiscal year.
NCI is establishing an Early-Onset Cancer Initiative to address the reported rise in early-onset cancer. The initiative will focus on the biological mechanisms of early-onset cancer, the interactions between several known risk factors, and prevention strategies.
The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.
President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.
NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.
NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.
Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.
Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level.
A multi-million-dollar global research initiative is bringing together the international scientific community to help identify and tackle the toughest challenges in cancer research, with input from patient advocates.
